Sales Contract between Si4Health & BayerInnovation
The Si4Health GmbH has signed a sales contract covering diverse industrial property rights with Bayer Innovation GmbH, a 100% subsidiary of Bayer AG Leverkusen. Si4Health GmbH develops, produces and markets novel cell substrate materials for tissue replacement in the area of Tissue Engineering. Patients with mild to severe skin injuries are offered a palette of products for wound healing. These range from active plasters which speed up the healing process in smaller wounds to complete reconstruction of the skin in larger areas caused by burns and ulcers. Silica is an important component of human connective tissue, hair, teeth and skin. The new material has the advantage that it does not cause inflammatory or rejection reactions and can be broken down neutrally in the body. Bayer Innovation GmbH identifies areas of growth, offering new business opportunities. Over 300 fields have been examined; demands and types of technology have been evaluated. Markets such as energy, electronics, materials, security and medicine are correlated with trends such as mobility, function, biotolerability, individualisation and miniaturisation. Medical technology is a new business field to commence with, an area in which good rates of growth are expected to follow and where there is a call for broad-based innovation - a good starting point for Bayer with its experience in health care and material science.
For more information see: